French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version.

Humans Idiopathic Pulmonary Fibrosis / diagnosis Lung / pathology Prognosis Tomography, X-Ray Computed / methods Lung Transplantation
Biopsy Interstitial lung disease Pulmonary fibrosis Usual interstitial pneumonia

Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 9 6 2023
pubmed: 12 1 2023
entrez: 11 1 2023
Statut: ppublish

Résumé

Since the latest 2017 French guidelines, knowledge about idiopathic pulmonary fibrosis has evolved considerably. Practical guidelines were drafted on the initiative of the Coordinating Reference Center for Rare Pulmonary Diseases, led by the French Language Pulmonology Society (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of the entire OrphaLung network, pulmonologists practicing in various settings, radiologists, pathologists, a general practitioner, a health manager, and a patient association. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS), including an online vote using a Likert scale. After a literature review, 54 guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease: epidemiology, diagnostic procedures, quality criteria and interpretation of chest CT scans, lung biopsy indication and procedures, etiological workup, methods and indications for family screening and genetic testing, assessment of the functional impairment and prognosis, indication and use of antifibrotic agents, lung transplantation, management of symptoms, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. These evidence-based guidelines are intended to guide the diagnosis and practical management of idiopathic pulmonary fibrosis.

Sections du résumé

BACKGROUND BACKGROUND
Since the latest 2017 French guidelines, knowledge about idiopathic pulmonary fibrosis has evolved considerably.
METHODS METHODS
Practical guidelines were drafted on the initiative of the Coordinating Reference Center for Rare Pulmonary Diseases, led by the French Language Pulmonology Society (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of the entire OrphaLung network, pulmonologists practicing in various settings, radiologists, pathologists, a general practitioner, a health manager, and a patient association. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS), including an online vote using a Likert scale.
RESULTS RESULTS
After a literature review, 54 guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease: epidemiology, diagnostic procedures, quality criteria and interpretation of chest CT scans, lung biopsy indication and procedures, etiological workup, methods and indications for family screening and genetic testing, assessment of the functional impairment and prognosis, indication and use of antifibrotic agents, lung transplantation, management of symptoms, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis.
CONCLUSION CONCLUSIONS
These evidence-based guidelines are intended to guide the diagnosis and practical management of idiopathic pulmonary fibrosis.

Identifiants

DOI: 10.1016/j.resmer.2022.100948 PMID: 36630775
pubmed: 36630775
pii: S2590-0412(22)00064-2
doi: 10.1016/j.resmer.2022.100948
pii:
doi:

Types de publication

Review Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

100948

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Vincent Cottin (V)

National Coordinating Reference Center for Rare Lung Diseases, Pneumonology Department, Louis Pradel Hospital, Hospices Civils de Lyon (HCL), UMR 754, IVPC, INRAE, Member of OrphaLung, RespiFil, Radico-ILD2 and ERN-LUNG, Lyon University, Claude Bernard Lyon 1 University, 28 avenue Doyen Lépine, Lyon F-69677 CEDEX, France. Electronic address: vincent.cottin@chu-lyon.fr.

Philippe Bonniaud (P)

Constitutive Reference Center for Rare Lung Diseases, Bourgogne University Hospital Center and Faculty of Medicine and Pharmacy, Bourgogne-Franche Comté University, INSERM U123-1, Dijon, France.

Jacques Cadranel (J)

Constitutive Reference Center for Rare Lung Diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Tenon Hospital, Sorbonne University, GRC 04 Theranoscan, Paris, France.

Bruno Crestani (B)

Constitutive Reference Center for Rare Lung Diseases, Pneumonology Department A, AP-HP, Bichat Hospital, Paris, France.

Stéphane Jouneau (S)

Expert Center for Rare Lung Diseases in Adults, Pneumonology Department, Pontchaillou Hospital, IRSET UMR1085, Rennes 1 University, Rennes, France.

Sylvain Marchand-Adam (S)

Expert Center for Rare Lung Diseases in Adults, Pneumonology Department, CHRU, Bretonneau Hospital, Tours, France.

Hilario Nunes (H)

Constitutive Reference Center for Rare Lung Diseases, Pneumonology Department, Avicenne Hospital, Bobigny, AP-HP, Sorbonne Paris Nord University, Bobigny, France.

Lidwine Wémeau-Stervinou (L)

Constitutive Reference Center for Rare Lung Diseases, Heart-Lung Institute, Pneumonology and Immuno-allergology Department, CHRU of Lille, Lille, France.

Emmanuel Bergot (E)

Expert Center for Rare Lung Diseases in Adults, Pneumonology Department, Pneumonology and Thoracic Oncology Department, Côte de Nacre Hospital, Caen University Hospital Center, Caen, France.

Elodie Blanchard (E)

Expert Center for Rare Lung Diseases in Adults, Pneumonology Department, Haut Levêque Hospital, Bordeaux University Hospital Center, Pessac, France.

Raphaël Borie (R)

Constitutive Reference Center for Rare Lung Diseases, Pneumonology Department A, AP-HP, Bichat Hospital, Paris, France.

Arnaud Bourdin (A)

Expert Center for Rare Lung Diseases in Adults, Pneumonology and Addictology Department, INSERM U1046, CNRS UMR 921, Arnaud de Villeneuve Hospital, Montpellier University Hospital Center, Montpellier, France.

Cécile Chenivesse (C)

Constitutive Reference Center for Rare Lung Diseases, Pneumonology and Immuno-allergology Department, Albert Calmette Hospital, Lille Regional University Hospital Center, Infection and Immunity Center of Lille U1019 - UMR 9017, Lille University, Lille University Hospital Center, CNRS, Inserm, Pasteur Institute of Lille, Lille, France.

Annick Clément (A)

Resource and Expert Center for Pediatric Cystic Fibrosis, Reference Center for Rare Respiratory Diseases (RespiRare), Pediatric Pneumonology Department, Armand Trousseau Children's Hospital, Paris Est University Hospital Center, Sorbonne University, Paris, France.

Emmanuel Gomez (E)

Expert Center for Rare Lung Diseases, Pneumonology Department, Brabois Hospitals, Nancy Regional University Hospital Center, Vandoeuvre-les Nancy, France.

Anne Gondouin (A)

Expert Center for Rare Lung Diseases, Pneumonology Department, HP, Jean Minjoz Univerty Hospital Center, Besançon, France.

Sandrine Hirschi (S)

Expert Center for Rare Lung Diseases, Pneumonology Department, New Civil Hospital, Strasbourg, France.

François Lebargy (F)

Expert Center for Rare Lung Diseases, Pneumonology Department, Maison Blanche University Hospital Center, Reims, France.

Charles-Hugo Marquette (CH)

Expert Center for Rare Lung Diseases, FHU OncoAge, Nice cedex 1, Pneumonology and Thoracic Oncology Department, Institute of Research on Cancer and Aging (IRCAN), Pasteur Hospital, Nice University Hospital Center, Côte d'Azur University, CNRS, INSERM, Nice, France.

David Montani (D)

Expert Center for Rare Lung Diseases, National Coordinating Reference Center for Pulmonary Hypertension, Pneumonology and Pneumological Intensive Care Unit, DMU 5 Thorinno, Inserm UMR S999, Faculty of Medicine, AP-HP, Paris-Sud University Hospital Center, Bicêtre Hospital, Paris-Saclay University, Le Kremlin-Bicêtre, France.

Grégoire Prévot (G)

Expert Center for Rare Lung Diseases, Pneumonology Department, Larrey University Hospital Center, Toulouse, France.

Sébastien Quetant (S)

Expert Center for Rare Lung Diseases, Pneumonology and Physiology Department, Grenoble Alpes University Hospital Center, Grenoble, France.

Martine Reynaud-Gaubert (M)

Expert Center for Rare Lung Diseases, Pneumonology Department, AP-HM, Nord University Hospital Center, Marseille, Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Mathieu Salaun (M)

Expert Center for Rare Lung Diseases, Pneumonology, Thoracic Oncology and Respiratory Intensive Care Department & CIC 1404, Charles Nicole Hospital, Rouen University Hospital Center, IRIB, QuantiIF-LITIS Laboratory, EA 4108, Rouen University, Rouen, France.

Olivier Sanchez (O)

Expert Center for Rare Lung Diseases, Pneumonology and Intensive Care Department, Georges Pompidou European Hospital, AP-HP, Paris, France.

Bruno Trumbic (B)

Cap Evidence, Paris, France.

Karim Berkani (K)

Pierre de Soleil Clinic, Vetraz Monthoux, France.

Pierre-Yves Brillet (PY)

UPRES EA 2363, Radiology Department, AP-HP, Avicenne Hospital, Paris 13 University, Bobigny, France.

Marion Campana (M)

Pneumonology and Thoracic Oncology Department, Orléans Regional Hospital Center, Orléans, France.

Lara Chalabreysse (L)

Pathological Anatomy Department, East Hospital Group, HCL, Bron, France.

Gérard Chatté (G)

Pneumonology Practice and Protestant Infirmary, Caluire, France.

Didier Debieuvre (D)

Pneumonology Department, GHRMSA, Emile Muller Hospital, Mulhouse, France.

Gilbert Ferretti (G)

Diagnostic and Interventional Radiology Department, Grenoble Alpes University Hospital Center, Grenoble Alpes University, Grenoble, France.

Jean-Michel Fourrier (JM)

Pierre Enjalran Association for Idiopathic Pulmonary Fibrosis (APEFPI), Meyzieu, France.

Nicolas Just (N)

Pneumonology Department, Victor Provo Hospital Center, Roubaix, France.

Marianne Kambouchner (M)

Pathology Department, AP-HP, Avicenne Hospital, Bobigny, France.

Bertrand Legrand (B)

Medical Practice of Bourgogne, ULR 2694 METRICS, CERIM, Lille University, Lille University Hospital Center, Tourcoing, Lille, France.

Frédéric Le Guillou (F)

Pneumonology Practice, Esquirol Health Pole, Le Pradet, France.

Jean-Pierre Lhuillier (JP)

Pneumonology Practice, La Varenne Saint-Hilaire, France.

Anas Mehdaoui (A)

Pneumonology and Thoracic Oncology Department, Eure-Seine Hospital Center, Évreux, France.

Jean-Marc Naccache (JM)

Pneumonology, Allergology and Thoracic Oncology Department, Paris Saint-Joseph Hospital Group, Paris, France.

Catherine Paganon (C)

Pneumonology Department, Louis Pradel Hospital, HCL, Bron, France.

Martine Rémy-Jardin (M)

Heart-Lung Institute, Radiology and Thoracic Imaging Department, Lille Regional University Hospital Center, Lille, France.

Salim Si-Mohamed (S)

Cardiovascular and Thoracic Imaging Department, Louis Pradel Hospital, HCL, INSA-Lyon, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, Lyon University, Claude Bernard Lyon 1 University, U1206, Villeurbanne, France.

Philippe Terrioux (P)

Pneumonology Practice, Meaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › French practical guidelines for the diagnosis...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Pneumopathies interstitielles › Fibrose pulmonaire idiopathique › French practical guidelines for the diagnosis...
questionsmedicales.fr › Appareil respiratoire › Poumon › French practical guidelines for the diagnosis...
questionsmedicales.fr › Diagnostic › Pronostic › French practical guidelines for the diagnosis...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Tomographie à rayons X › Tomodensitométrie › French practical guidelines for the diagnosis...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation d'organe › Transplantation pulmonaire › French practical guidelines for the diagnosis...